Environment, Inflammation and Metabolic Diseases Study
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 8,000
- 试验地点
- 1
- 主要终点
- The prevalence of autonomous secretion of aldosterone
研究概览
简要总结
The aim is to establish an effective and practical early warning model for endocrine and metabolic diseases based on an environmental-gene-protein panoramic network, to uncover new mechanisms underlying the onset and progression of these diseases, and to screen for novel therapeutic targets.
详细描述
This study aims to establish a specialized resource database for metabolic diseases-the Chongqing Environment, Inflammation, and Metabolic Diseases Study (EIMDS). The cohort will include approximately 8,000 community-based individuals who have been followed up for over 5 years, with clinical, biochemical, and endpoint event assessments conducted every two years, along with the collection of blood and urine samples. Based on the EIMDS cohort,this study will explore the risk factors for endocrine and metabolic diseases from a population perspective. Furthermore, by employing technologies such as whole-transcriptome sequencing, proteomics and phosphoproteomics, ATAC-seq, and single-cell sequencing,this study aim to elucidate the molecular mechanisms underlying endocrine and metabolic diseases and identify potential drug targets.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •All individuals who voluntarily participated in the physical examination
排除标准
- •Participants with incomplete data
研究组 & 干预措施
hypertension group
Participants with hypertension
干预措施: observe (Other)
DM group
Participants with diabetes mellitus
干预措施: observe (Other)
AAS group
Participants with autonomous aldosterone secretion (AAS)
干预措施: observe (Other)
结局指标
主要结局
The prevalence of autonomous secretion of aldosterone
时间窗: The follow-up period from baseline enrollment to the completion of follow-up examinations was approximately 5 years
The primary outcome is the prevalence of autonomous aldosterone secretion at baseline. Autonomous aldosterone secretion is defined by plasma aldosterone concentration (PAC) ≥100 pg/mL combined with plasma renin concentration (PRC) ≤15 uIU/mL in study participants at enrollment. Prevalence will be calculated as the number of participants meeting the above biochemical criteria divided by the total enrolled participants in the target population, presented as percentage with corresponding 95% confidence interval.
次要结局
- Identification of key risk factors associated with autonomous aldosterone secretion(The follow-up period from baseline enrollment to the completion of follow-up examinations was approximately 5 years)
- Association of autonomous aldosterone secretion with chronic kidney disease and metabolic disorders(The follow-up period from baseline enrollment to the completion of follow-up examinations was approximately 5 years)
- Screening of key proteins, signaling pathways and potential biomarkers associated with autonomous aldosterone secretion using proteomic analysis(The follow-up period from baseline enrollment to the completion of follow-up examinations was approximately 5 years)
研究者
Qifu Li
Chief Physician, Department of Endocrinology, The First Affiliated Hospital of Chongqing Medical University.
Chongqing Medical University